ClinicalTrials.gg
RecruitingNCT07121972Updated Nov 10, 2026

Mirai-MRI: Validation of AI Models for Breast Cancer Risk

An interventional study of Magnetic resonance imaging (MRI) and Artificial Intelligence (AI) in Cancer Risk and Breast Cancer Risk, sponsored by University of California, San Francisco. Recruiting at 4 sites in United States. Open to female participants aged 40 Years to 89 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by University of California, San Francisco · Not applicable, Interventional, and Screening

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
400
Allocation
Not applicable
Ages
40 Years to 89 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 62 studies in Breast Neoplasms by University of California, San Francisco — 11 open to participants now, 16 under way, 1 of them phase 3. Breast Neoplasms · University of California, San Francisco.

Planned enrollment
4th of 49
400 · median 38
Started
2025
with 2 others
No phase
23 of 62
4 open now
Primary completion
2027-01
later than 1 of 15 live
Registered
58th of 62
by date

Among the 62 studies in Breast Neoplasms by University of California, San Francisco, this one is the 4th largest by planned enrollment of the 49 interventional ones that give a count, is one of 3 that started in 2025, is one of 23 with no phase, reaches primary completion later than 1 of the 15 other live ones, and was the 58th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

11 of the 62 studies in Breast Neoplasms by University of California, San Francisco are open now, in 1 country. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 40 Years to 89 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 62 studies in Breast Neoplasms by University of California, San Francisco, or all of them as a file.
02

Study summary

This is a multi-center, single arm trial to evaluate the cancer detection rate of supplemental screening magnetic resonance imaging (MRI) in participants who are high-risk by Mirai-MRI assessment. Mirai is an accurate cancer risk model based on full-resolution mammograms.

Read the detailed description

PRIMARY OBJECTIVE:

I. To estimate the cancer detection rate (CDR) of supplemental screening breast MRI in participants who are high-risk by the Mirai model

SECONDARY OBJECTIVES:

I. To estimate the CDR of supplemental screening breast MRI in participants with high Mirai risk and low (\<20%) lifetime Tyrer-Cuzick (TC) risk.

II. To compare the CDR of supplemental screening breast MRI in participants with high Mirai risk and high (≥ 20%) lifetime TC risk versus CDR in participants with high Mirai risk and low (\<20%) lifetime TC risk.

III. To estimate the positive predictive value (PPV)1, PPV2, and PPV3 of supplemental MRI screening in participants with high Mirai risk.

IV. To estimate the false positive rate (1 - specificity) of supplemental screening MRI in participants with high Mirai risk.

V. To evaluate the tumor size, stage, grade, histological and molecular subtypes, Ki-67 percentage, and lymph node involvement of cancers detected on supplemental screening MRI in Mirai high risk participants.

VI. To evaluate the association between race/ethnicity, menopausal status, hormonal status, breast density, family history of cancer, and CDR in Mirai high-risk participants.

03

Conditions studied

  • Cancer Risk
  • Breast Cancer Risk

Browse trials for

Keywords

  • Screening
  • BI-RADS
04

Who can participate

Ages eligible
40 Years to 89 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. All asymptomatic participants assigned female at birth, ages 40-89 years old with screening mammography assessed as Breast Imaging Reporting and Data System (BI-RADS) 1, BI-RADS 2, or initial BI-RADS 0 with subsequent diagnostic mammogram assessed as BI-RADS 1 or BI-RADS 2.
  2. Screening mammogram assessed as high-risk by Mirai (top 3 percentile of 2-year risk).
  3. Availability of a routine screening mammogram report, along with a subsequent diagnostic mammogram report if applicable, and access to the corresponding Digital Imaging and Communications in Medicine (DICOM) images.
  4. Ability to understand and the willingness to sign a written document.

Exclusion criteria

Exclusion Criteria:

  1. Screening mammogram that is assessed as BI-RADS 0 for technical recall.
  2. for MRI:

    1. Metallic foreign body in the eye.
    2. MRI unsafe implants and/or medical devices.
    3. Adverse reaction to a (gadolinium-based) contrast agent in the past.
    4. Pregnant women.
    5. Claustrophobia.
    6. Exceeds site specific size and/or weight limit for MRI.
  3. If the participant meets site-specific criteria for screening estimated (eGFR) prior to MRI, participants with severely impaired renal function (GFR \< 30 mL/min) will be excluded. According to University of California, San Francisco's policy for MRI with contrast (gadolinium-containing), serum creatinine with calculation of eGFR should be obtained within 6 weeks of the MRI study for participants with any of the following risk factors:

    1. History of "kidney disease" as an adult, including renal tumor or transplant.
    2. Diabetes treated with insulin or other prescribed medications.
    3. Hypertension (high blood pressure) requiring medication.
    4. Multiple myeloma.
    5. Solid organ transplant.
    6. History of severe hepatic disease/liver transplant/pending liver transplant.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    Supplemental MRI

    Participants identified as Mirai high-risk on a negative/benign screening mammogram will receive a supplemental MRI within 12 months of receiving a screening mammogram. Breast cancer risk following the Tyrer-Cuzick risk model will be assessed for comparison.

    Procedure: Magnetic resonance imaging (MRI) · Device: Artificial Intelligence (AI)

Interventions

  • ProcedureMagnetic resonance imaging (MRI)

    Undergo Magnetic resonance (MR) imaging

    Also known as: MRI, MRI Scan

  • DeviceArtificial Intelligence (AI)

    AI applied to MRI images

    Also known as: AI Models, AI Algorithm

06

What researchers measure

Primary outcomes

  1. Cancer detection rate (CDR)

    The CDR is defined as the number of breast cancers identified per 1,000 magnetic resonance imaging (MRI) screening examinations performed 1 year following supplemental screening MRI.

    Time frame: Up to 1 year

Secondary outcomes

  1. CDR of participants designated as low risk using the Tyrer-Cuzick (TC) criteria

    Cancer detection rate is defined as the number of breast cancers identified per 1,000 MRI screening examinations performed of supplemental screening breast MRI in participants with high Mirai risk and low (\<20%) lifetime TC risk.

    Time frame: Up to 1 year

  2. Comparison of CDR in low and high TC risk groups

    The CDR of supplemental screening breast MRI in participants with high Mirai risk and high (≥ 20%) lifetime TC risk versus CDR in participants with high Mirai risk and low (\<20%) lifetime TC risk will be compared using a two-proportion exact test.

    Time frame: Up to 1 year

  3. Positive predictive value of supplemental MRI screening and BI-RADS Score (PPV1)

    PPV1 is the percentage of all positive supplemental MRI screening in participants with high Mirai risk (Breast Imaging Reporting and Data System (BI-RADS) 3, 4, or 5) for which the participant was found to be positive for cancer within 1 year from the time of MRI.

    Time frame: Up to 1 year

  4. Positive predictive value of supplemental MRI screening recommending histological or surgical follow-up (PPV2)

    PPV2 is the percentage of all supplemental MRI screenings in participants with high Mirai risk recommended for tissue diagnosis or surgical consultation (BI-RADS 4 and 5) that resulted in a histological diagnosis of cancer within 1 year.

    Time frame: Up to 1 year

  5. Positive predictive value of biopsies resulting in histological diagnosis (PPV3)

    PPV3 is the percentage of all known biopsies performed as a result of positive supplemental MRI screening (BI-RADS 4 or 5) that resulted in a tissue diagnosis of cancer within 1 year.

    Time frame: Up to 1 year

  6. False Positive Rate (FPR)

    A false positive is defined as an imaging result that incorrectly identifies a condition as present. The FPR = (False Positives / Total Tests) × 100 (or 1 - specificity) of results on supplemental screening MRIs in participants with high Mirai risk.

    Time frame: Up to 1 year

  7. Mean tumor size detected in supplemental imaging

    Mean tumor size in millimeters (mm) with in situ and invasive components separately on supplemental screening MRI in Mirai high risk participants.

    Time frame: Up to 1 year

  8. Frequency of tumor stage detected in supplemental imaging

    The frequency of tumor stage diagnosed using the supplemental screening MRI in Mirai high risk participants will be reported.

    Time frame: Up to 1 year

  9. Proportion of participants with Ki-67 expressed biomarker

    Ki-67 is divided according to percentage levels: \< 15% and \> 15%. The proportion of participants with pathologically confirmed Ki-67 by percentage level will be reported.

    Time frame: Up to 1 year

  10. Proportion of participants with lymph node involvement detected in supplemental imaging

    The proportion of participants with demonstrated lymph node involvement of cancers detected on the supplemental screening MRI in Mirai high risk participants.

    Time frame: Up to 1 year

  11. Correlation between race/ethnicity and CDR

    The Spearman's correlation coefficient (rs) will be used to measure the strength and direction of association between race/ethnicity and CDR. The Spearman correlation coefficient, rs, results in values from +1 to -1 where a value of +1 indicates a perfect association, and rs of 0 indicates no association and an rs of -1 indicates a perfect negative association. The closer rs is to 0, the weaker the association

    Time frame: Up to 1 year

  12. Correlation between menopausal status and CDR

    The Spearman's correlation coefficient (rs) will be used to measure the strength and direction of association between menopausal status and CDR. The Spearman correlation coefficient, rs, results in values from +1 to -1 where a value of +1 indicates a perfect association, and rs of 0 indicates no association and an rs of -1 indicates a perfect negative association. The closer rs is to 0, the weaker the association

    Time frame: Up to 1 year

  13. Correlation between hormonal status and CDR

    The Spearman's correlation coefficient (rs) will be used to measure the strength and direction of association between hormonal status and CDR. The Spearman correlation coefficient, rs, results in values from +1 to -1 where a value of +1 indicates a perfect association, and rs of 0 indicates no association and an rs of -1 indicates a perfect negative association. The closer rs is to 0, the weaker the association.

    Time frame: Up to 1 year

  14. Correlation between breast density and CDR

    The Pearson correlation coefficient (r) will be used to measure the strength and direction of association between breast density and CDR. The Pearson correlation coefficient (r) can take values from +1 to -1 where a value of +1 indicates a perfect association, a value of 0 indicates no association, and a value of -1 indicates a perfect negative association. The closer r is to 0, the weaker the association.

    Time frame: Up to 1 year

  15. Correlation between family history of cancer and CDR

    The Spearman's correlation coefficient (rs) will be used to measure the strength and direction of association between history of cancer and CDR. The Spearman correlation coefficient, rs, results in values from +1 to -1 where a value of +1 indicates a perfect association, and rs of 0 indicates no association and an rs of -1 indicates a perfect negative association. The closer rs is to 0, the weaker the association.

    Time frame: Up to 1 year

07

Study locations

2 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified data may be shared with research collaborators during the course of the study.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Jan 2027, 14 months after the start.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 14 months is below that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 6, 2025
First posted
Aug 14, 2025
StartActual
Nov 3, 2025
Primary completionEst.
Jan 31, 2027
CompletionEst.
Jan 31, 2027
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07121972
Collaborators
Breast Cancer Research Foundation
Responsible party
Sponsor
First posted
Aug 14, 2025
Start date
Nov 3, 2025
Primary completion
Jan 31, 2027 (estimated)
Completion
Jan 31, 2027 (estimated)
Last update
Nov 10, 2026

Study contacts

Tiffany Tran
Contact
tiffany.tran3@ucsf.edu
877-827-3222
Maggie Chung, MD
principal investigator · University of California, San Francisco

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion